References
1Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019;71:1599-613.
2Chen J, Veras MMS, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD004524.
3Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, Tam LS. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 2008;47:1358-63.
4Nissen MJ, Ciurea A, Bernhard J, et al. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis. Arthritis Rheumatol 2016;68:2141-50.
5George MD, Baker JF, Ogdie A. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol 2020;47:826-34.
6Ducourau E, Rispens T, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of ADA in axial spondyloarthritis: a multicentric randomised trial. RMD Open 2020;6:e001047
7Dougados M, Maksymowych WP, Landewé RBM, et al. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of ETA therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritisAnn Rheum Dis 2018;77:221-7.
8Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol 2018;14:525-33.
9van der Heijde D, Baraliakos X, Hermann KGA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 2018;77:699-705.
10Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-5.
11Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-54.
12Torgutalp M, Rodriguez VR, Dilbaryan A, et al. Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 2022;81:1252-9.
13Baraliakos X, Gensler LS, D’Angelo S, et al. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literatüre review. Ther Adv Musculoskel Dis 2020;12:1-17.
14Boers N, Michielsens CAJ, van der Heijde D, den Broeder AA, Welsing PMJ. The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. Rheumatology (Oxford) 2019;58:1907-22.
15Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J. Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Rheumatology (Oxford) 2018;57:703-11.
16Varkas G, Thevissen K, De Brabanter G, et al. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis 2017;76:878-81.
17Roblin X, Paul S, Ben-Horin S. Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy. J Crohns Colitis 2018;12:379-80.
18Dubash S, Marianayagam T, Tinazzi I, et al. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology (Oxford) 2019;58:963-8.
19Dupré A, Collins M, Nocturne G, Carbonnel F, Mariette X, Seror R. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Rheumatology (Oxford) 2020;59:3275-83.
20Glintborg B, Lindström U, Giuseppe DD, et al. Danish Rheumatology Database (DANBIO), Anti-Rheumatic Therapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN), and Norwegian Antirheumatic Drug Register (NOR-DMARD) registries. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care Res (Hoboken) 2022;74:748-58.
21Lindström U, Bengtsson K, Olofsson T, et al. Anterior uveitis in patients with spondyloarthritis treated with Secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann Rheum Dis 2021;80:1445-52.
22Kiltz U, Brandt-Jrgens J, Kastner P, et al. Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study. [abstract]. Arthritis Rheum 2021;73:Suppl 10.
23Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with Secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019;78:473-9.
24Petitpain N, D’Amico F, Yelehe-Okouma M, et al. IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. Clin Pharmacol Ther 2021;110:159-68.
25Stolwijk C, Essers I, van Tubergen A, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 2015;74:1373-8.
26Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
27Van Praet L, van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013;72:414-7.
28Landewé RBM, van der Heijde D, Dougados M, et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann Rheum Dis 2020;79:920-8.
29Landewé RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis 2021;80:1022-30.
30Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing ADA therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 2018;392:134-44.
31Almirall M, Salman-Monte TC, Lisbona MP, Maymó J. Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: Are there any differences between patients who relapsed and to those who remained in low disease activity? Rheumatol Int 2015;35:1565-8.
32Maksymowych W, Inman R, Bessette L, et al. Sustained functional remission in axial spondyloarthritis (axSpA); which are the primary outcomes that should be targeted to achieve this? [abstract] Arthritis Rheum 2021;73(Suppl 10).
33Wetterslev M, Georgiadis S, Christiansen SN, et al. Tapering of TNF inhibitors in patients with axial spondyloarthritis- can flare be predicted. [abstract] Arthritis Rheum 2021;73(Suppl 10).
34Michielsens CAJ, den Broeder N, van den Hoogen FHJ, et al. Treat-to- target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial Ann Rheum Dis 2022;81:1392-9.
